The Potential Benefits and Limitations of Medical Cannabis

Medical cannabis occupies an unusual place in modern healthcare. Millions of patients use cannabis with the goal of managing symptoms, and many states—including Arizona—have established medical marijuana programs. At the same time, the scientific evidence supporting cannabis varies considerably depending on the medical condition, cannabinoid, formulation, dose, and outcome being studied.

For some patients, cannabis may provide meaningful symptom relief. For others, the improvement may be small, inconsistent, or outweighed by side effects.

That distinction matters.

Medical cannabis should not be viewed as either a cure-all or a treatment without legitimate therapeutic potential. A more useful approach is to examine what current research actually supports, where evidence remains uncertain, and how the potential benefits compare with the limitations and risks for an individual patient.

Patients who want to understand the underlying physiology can also read How Medical Cannabis Affects the Body.

Medical Cannabis Is Not One Standardized Treatment

One of the first challenges in discussing medical cannabis is that the term does not describe a single medication.

Cannabis products can differ substantially in:

• THC concentration

• CBD concentration

• THC-to-CBD ratio

• other cannabinoid content

• method of administration

• dose

• onset and duration of effects

• frequency of use

• manufacturing and formulation

A high-THC inhaled product may produce very different effects from a lower-THC oral product, a balanced THC-and-CBD formulation, or a CBD-dominant preparation.

Individual response also varies. Age, previous cannabis exposure, metabolism, medications, medical conditions, mental health history, and the symptom being treated can all influence how a person responds.

This variability is one reason findings from a study involving one standardized cannabinoid product cannot automatically be applied to every product available to patients.

What Potential Benefits Does the Research Support?

Cannabis and cannabinoids have been studied for numerous medical conditions. The strength of evidence, however, is not equal across those conditions.

The National Center for Complementary and Integrative Health notes that cannabinoid-containing medications have demonstrated usefulness for certain rare seizure disorders, chemotherapy-associated nausea and vomiting, and appetite or weight-loss problems associated with HIV/AIDS. There is also evidence suggesting modest benefits for some forms of chronic pain and symptoms associated with multiple sclerosis.

Importantly, some of this research involves standardized pharmaceutical cannabinoids rather than dispensary marijuana products. The evidence should therefore be interpreted according to the specific treatment that was actually studied.

Potential Benefit for Certain Types of Chronic Pain

Chronic pain is one of the most frequently discussed reasons for medical cannabis use.

Cannabinoid receptors and the body's endocannabinoid system participate in neurological pathways involved in pain perception, which provides a biological rationale for studying cannabinoids as pain-modulating therapies.

Clinical evidence suggests that certain cannabinoid products may produce small improvements in chronic pain, particularly in populations with neuropathic pain.

The 2025 Agency for Healthcare Research and Quality review of cannabinoids for chronic pain included 29 randomized controlled trials involving 2,579 participants. Studies were predominantly short-term, and nearly half involved neuropathic pain.

For certain comparable THC-to-CBD products, researchers found a small decrease in pain severity compared with placebo. Higher-THC formulations also produced small improvements in pain in some studies. However, improvement in function was less consistent, and adverse effects were more common.

This is an important distinction for patients.

Reducing a pain score somewhat is not necessarily the same as restoring mobility, improving function, returning to exercise, or treating the underlying source of pain.

For musculoskeletal pain in particular, cannabis may sometimes be considered as one component of a broader integrative pain management approach that may also involve diagnostic evaluation, rehabilitation, movement, lifestyle changes, medications, targeted procedures, or other therapies.

Potential Benefit for Muscle Spasticity

Cannabinoids have also been studied in neurological conditions involving muscle spasticity, particularly multiple sclerosis.

Research summarized by the National Institutes of Health suggests that certain cannabinoid preparations may reduce spasticity or related symptoms in some individuals with multiple sclerosis, although results vary and not every preparation has demonstrated the same benefit.

Patients should again distinguish between evidence involving standardized cannabinoid medications and the broader assortment of cannabis products available outside pharmaceutical studies.

Nausea and Vomiting

Cannabinoid medications have an established history of investigation for nausea and vomiting associated with chemotherapy.

Several prescription cannabinoid medications have FDA-approved indications related to chemotherapy-associated nausea and vomiting. This provides evidence that cannabinoid pathways can have legitimate therapeutic effects on nausea.

However, it does not mean that every cannabis product should be considered equivalent to those medications.

The FDA distinguishes standardized approved cannabinoid medications from marijuana itself. The agency has not approved the cannabis plant as a treatment for a disease or medical condition, although it has approved specific cannabis-derived or cannabis-related prescription medications for defined indications.

Appetite and Weight Loss in Selected Conditions

THC can stimulate appetite in some individuals.

This effect may be undesirable for one patient but potentially useful for another—particularly in certain conditions associated with poor appetite or wasting.

Prescription cannabinoid medications have been studied and approved for specific appetite-related indications, including anorexia associated with weight loss in patients with AIDS.

Again, evidence involving a pharmaceutical cannabinoid should not automatically be interpreted as evidence that any cannabis product, dose, or method of administration will provide the same result.

Symptom Relief Does Not Necessarily Mean Disease Treatment

This may be the most important limitation to understand.

Cannabis can alter how a patient experiences a symptom without necessarily correcting the condition producing that symptom.

For example, cannabis might reduce a patient's perception of pain without repairing:

• a torn tendon

• nerve compression

• joint instability

• advanced osteoarthritis

• an inflammatory disorder

• another structural or medical cause of pain

Similarly, improving nausea does not necessarily identify or treat the reason nausea is occurring.

Medical cannabis may therefore function primarily as symptom-management or palliative therapy in many situations rather than as a treatment that changes the underlying disease process.

A reduction in symptoms can still be meaningful. But symptom improvement should not prevent appropriate diagnostic evaluation or treatment of the underlying condition.

The Average Benefit May Be Modest

Medical cannabis discussions sometimes become polarized between claims that cannabis is ineffective and claims that it can treat an enormous range of medical conditions.

The evidence supports a more nuanced conclusion.

Certain cannabinoid therapies appear to help certain symptoms in some patients—but the average magnitude of benefit in many studies is relatively modest.

For chronic pain, for example, the 2025 AHRQ review found small improvements in pain with several cannabinoid formulations while also finding increases in adverse effects such as dizziness, sedation, and nausea.

A treatment does not need to eliminate a symptom completely to be worthwhile. A modest improvement may still matter if it helps someone sleep, walk, work, exercise, or participate more comfortably in everyday life.

The question is whether the improvement is meaningful for that particular patient and whether the benefits justify the disadvantages.

Side Effects Can Limit Treatment

The physiological effects responsible for potential benefits can also create unwanted effects.

THC-containing cannabis may cause:

• dizziness

• sedation

• impaired concentration

• short-term memory changes

• slower reaction time

• altered judgment

• impaired coordination

• anxiety

• panic

• paranoia

• increased heart rate

• changes in blood pressure

Higher THC exposure generally increases the likelihood of intoxication and impairment.

In the AHRQ chronic-pain review, certain THC-and-CBD formulations were associated with substantially higher rates of dizziness and sedation compared with placebo.

A patient who experiences less pain but becomes too sedated to work, exercise, drive safely, or function normally may not be experiencing an overall clinical benefit.

Cannabis Can Affect Driving and Safety-Sensitive Activities

Feeling subjectively comfortable does not necessarily mean someone is unimpaired.

Cannabis can slow reaction time, impair coordination, alter perception, and affect decision-making. The CDC specifically identifies impaired reaction time, coordination, perception, and decision-making as important cannabis-related safety concerns.

Patients should not drive, operate machinery, or perform other safety-sensitive activities while impaired.

This consideration can be particularly important for patients whose occupations involve driving, heavy machinery, healthcare responsibilities, construction, law enforcement, aviation, or other activities in which impaired reaction time could endanger themselves or others.

Cannabis Can Become Problematic With Frequent Use

Medical purpose does not eliminate the possibility of problematic use.

Some individuals who use cannabis develop cannabis use disorder, characterized by continued cannabis use despite health, occupational, social, or other problems.

The CDC estimates that approximately 3 in 10 people who use cannabis meet criteria for cannabis use disorder, although individual risk varies substantially. More frequent use and beginning cannabis use at a younger age are associated with greater risk.

Tolerance can also develop, meaning a patient may begin requiring greater exposure to produce the same perceived effect.

Patients using cannabis regularly should periodically reconsider whether it continues to provide meaningful benefit and whether the dose or frequency has gradually increased.

Mental Health History Matters

Cannabis does not affect everyone psychologically in the same way.

Some individuals describe relaxation or improved comfort. Others experience anxiety, panic, suspiciousness, paranoia, or disorientation.

The CDC notes an association between cannabis use and psychosis, with a stronger association among individuals who begin using cannabis earlier or use it more frequently.

This does not mean that every person who uses cannabis will develop a psychiatric disorder.

It does mean that significant psychiatric history—including previous psychosis, severe paranoia, or certain other mental health conditions—should be discussed during a medical evaluation rather than ignored when considering cannabis.

CBD Is Not Automatically Risk-Free

Cannabidiol, or CBD, does not produce the characteristic intoxication associated with THC, but "non-intoxicating" should not be confused with "risk-free."

CBD may cause drowsiness or gastrointestinal symptoms and can interact with medications.

The FDA also notes that pharmacologic CBD exposure can affect liver function and can alter the way certain medications are metabolized.

Medication review is therefore important even when someone plans to use a CBD-dominant product.

Potential interactions can become particularly relevant when patients take multiple medications or medications with narrow therapeutic ranges.

Product Variability Is a Major Limitation

Traditional prescription medications typically undergo standardized manufacturing designed to produce a defined dose and predictable formulation.

Cannabis products can be considerably more variable.

Products may differ in:

• cannabinoid concentration

• THC-to-CBD ratio

• absorption

• onset of effect

• duration

• route of administration

• manufacturing

• labeling

• individual metabolism

An edible may behave very differently from an inhaled product. A concentrated THC preparation may produce effects that are substantially different from a lower-dose preparation.

This variability makes it difficult to speak about "medical cannabis" as though every product represents the same intervention.

It also complicates the interpretation of research because a clinical trial studying one preparation does not necessarily predict what will happen with another.

Long-Term Evidence Is More Limited Than Many Patients Realize

Another significant limitation is the duration of cannabis research.

Many randomized clinical trials examining cannabinoids last weeks or months rather than years.

The 2025 AHRQ chronic-pain review specifically noted that studies were primarily short term and that the overall strength of evidence for many comparisons remained low.

That means researchers generally know more about short-term symptom response than about the consequences of using specific cannabis formulations continuously for many years.

Questions involving long-term cognition, tolerance, dependence, cardiovascular effects, changes in dose requirements, and cumulative exposure remain important areas of ongoing research.

Cannabis Should Be Avoided During Pregnancy and Breastfeeding

Pregnancy and breastfeeding require particular caution.

The U.S. Food and Drug Administration advises against the use of THC, CBD, and marijuana in any form during pregnancy or while breastfeeding because of potential risks and incomplete safety information.

Patients who are pregnant, trying to become pregnant, or breastfeeding should discuss symptom-management alternatives with their healthcare professional.

Medical Cannabis Should Not Automatically Replace Established Treatments

Another misconception is that choosing cannabis necessarily means discontinuing conventional medical treatment.

That should not be assumed.

Depending on the condition, established treatments may have substantially stronger evidence or may address a mechanism that cannabis does not.

For chronic musculoskeletal pain, appropriate care might include rehabilitation, exercise, physical therapy, medications, diagnostic imaging, injections, or other targeted interventions.

For neurological or inflammatory disease, disease-modifying therapies may be necessary even if cannabis provides some symptomatic relief.

Likewise, evidence that cannabis decreases opioid requirements is not strong enough to assume that cannabis will automatically allow a patient to discontinue opioid medications. Reviews summarized by NCCIH have found inconsistent results regarding whether cannabinoids meaningfully reduce opioid use in people.

Medication changes should be made deliberately and with appropriate medical supervision.

Who May Be More Likely to Benefit?

There is no single profile that guarantees a favorable response.

Medical cannabis may be more reasonable to consider when:

• the patient has a clearly identified medical condition

• the symptom being targeted has some evidence of cannabinoid responsiveness

• conventional treatments have been inadequate, poorly tolerated, or insufficient

• the treatment goal is clearly defined

• medication interactions have been reviewed

• the patient understands the possibility of impairment

• there is a plan for evaluating whether treatment is actually helping

The goal should not simply be to use cannabis.

The goal should be to achieve a measurable improvement in symptoms, function, or quality of life with acceptable risk.

Who Should Be Especially Cautious?

Additional caution may be appropriate for patients with:

• significant cardiovascular disease

• a history of psychosis or serious cannabis-related psychiatric effects

• cognitive impairment

• a high risk of falls

• a history of problematic cannabis or substance use

• medications that may interact with cannabinoids

• substantial sensitivity to sedation or dizziness

• occupations requiring driving or safety-sensitive activities

• pregnancy or breastfeeding

Age, medication burden, frequency of use, cannabinoid concentration, previous cannabis exposure, and other medical conditions may also affect risk.

Individual assessment is therefore more useful than attempting to create a universal list of people for whom cannabis is either always safe or always unsafe.

Arizona Medical Marijuana Eligibility Does Not Automatically Mean Cannabis Is Appropriate

Arizona operates a formal medical marijuana program through the Arizona Department of Health Services. Patients must meet state requirements and receive appropriate physician certification before applying as qualifying medical-marijuana patients.

However, having a qualifying diagnosis does not automatically mean cannabis is medically appropriate for every person with that diagnosis.

At Ask Dr. Hu, a medical marijuana evaluation includes review of the patient's diagnosis, symptoms, medical history, treatment experience, medications, potential interactions, and safety considerations before determining whether certification is medically appropriate.

Certification should be the result of an individualized medical assessment rather than an automatic approval based on diagnosis alone.

A Better Question Than "Does Medical Cannabis Work?"

The question "Does cannabis work?" is almost too broad to be clinically useful.

A better set of questions includes:

• What symptom are we trying to improve?

• What evidence exists for that particular symptom?

• Which cannabinoid formulation was actually studied?

• How much improvement is realistically expected?

• Does the patient function better?

• Are side effects acceptable?

• Are there medication interactions?

• Is cannabis masking a problem that still needs diagnosis or treatment?

• Is the patient requiring progressively larger amounts?

• Are there safer or more effective alternatives?

These questions turn cannabis use from a generalized idea into an individualized clinical decision.

The Bottom Line

Medical cannabis has legitimate therapeutic potential, but its benefits and limitations need to be considered together.

Research suggests that certain cannabinoid preparations can provide modest symptom relief for some patients, particularly in areas such as chronic pain, neuropathic pain, multiple-sclerosis-related symptoms, chemotherapy-associated nausea, and selected appetite-related conditions.

At the same time, cannabis is not a standardized treatment, does not reliably help every condition, and frequently does not address the underlying cause of symptoms.

Potential disadvantages include dizziness, sedation, cognitive impairment, anxiety, medication interactions, impaired driving ability, problematic use, and uncertainty about long-term effects.

The most appropriate question is therefore not simply whether medical cannabis is "good" or "bad."

The question is whether its potential benefits are meaningful enough—and its risks acceptable enough—to make it a reasonable option for a particular patient.

Arizona patients interested in learning more can explore the Medical Marijuana Resource Center, read Arizona Medical Marijuana: A Complete Guide for Patients, or request a physician-guided Arizona medical marijuana evaluation.

Certification is based on an individualized medical evaluation and is not guaranteed.

How This Article Was Developed

This article was written and medically reviewed by YiQiu Hu, NMD, an Arizona-licensed naturopathic physician.

The medical information was developed using current evidence and authoritative resources, including the Agency for Healthcare Research and Quality, National Center for Complementary and Integrative Health, U.S. Food and Drug Administration, Centers for Disease Control and Prevention, and Arizona Department of Health Services.

Current evidence demonstrates an important distinction between standardized cannabinoid medications studied in clinical trials and the wide variety of cannabis products available to consumers. Research also indicates that benefits vary substantially among medical conditions and should be weighed against potential adverse effects and individual risk factors.

Ask Dr. Hu's medical marijuana resources are periodically reviewed for changes in medical evidence, safety recommendations, and Arizona certification requirements.

Medical disclaimer: This article is intended for general educational purposes and does not replace individualized medical advice, diagnosis, or treatment. Cannabis is not appropriate for every patient. Do not drive, operate machinery, or perform safety-sensitive activities while impaired by cannabis.

About the Author

YiQiu Hu, NMD is an Arizona-licensed naturopathic physician and founder of Ask Dr. Hu. He provides concierge medicine, preventive healthcare, health optimization, medical marijuana evaluations, integrative pain management, laboratory testing, and individualized medical care for patients throughout Arizona.

Dr. Hu earned his Doctor of Naturopathic Medicine degree from Sonoran University of Health Sciences and a Bachelor of Science in Biomedical Sciences from Northern Arizona University. His clinical approach emphasizes thorough medical evaluation, evidence-informed care, clear patient education, and individualized treatment planning rather than one-size-fits-all recommendations.

Published August 2026 | Medically reviewed August 2026